Fri, Aug. 7, 7:40 AM
- BioCryst Pharmaceuticals (BCRX -4.1%) Q2 results: Revenues: $25.8M (+999%); R&D Expense: $16.5M (+48.6%); SG&A: $3.5M (+75.0%); Operating Income: $5.3M (+145.7%); Net Income: $4.9M (+133.6%); EPS: $0.06 (+126.1%); Quick Assets: $130.4M (+14.5%).
- 2015 Guidance: Net operating cash use: $18M - 28M; Operating expenses: $75M - 95M.
Fri, Aug. 7, 6:52 AM
Thu, Aug. 6, 5:30 PM
Thu, Jul. 2, 9:07 AM
- Onconova (NASDAQ:ONTX) upgraded to Overweight from Neutral with a $6 (131% upside) price target (up from $3) by Piper Jaffray.
- BioCryst Pharmaceuticals (NASDAQ:BCRX) upgraded to Buy from Neutral with a $19 (30% upside) price target (up from $12) by Bank of America.
- Kythera Biopharmaceuticals (NASDAQ:KYTH) downgraded to Market Perform from Outperform with a $65 (13% downside risk) price target (up from $61) by Leerink Swann.
- Zoetis (NYSE:ZTS) downgraded to Market Perform from Outperform with a $57 (18% upside) price target (up from $51) by BMO.
- China Cord Blood (NYSE:CO) downgraded to Neutral from Buy with a $6.75 (9% upside) price target (up from $6.50) by Roth Capital.
- Teladoc (Pending:TDOC) initiated with Outperform rating and $35 (23% upside) price target by RBC.
- Aldeyra (NASDAQ:ALDX) initiated with Buy rating and $16 (93% upside) price target by Canaccord Genuity.
- Novagen (NASDAQ:NVGN) initiated with Buy rating and $8.50 (89% upside) price target by H.C. Wainwright.
Fri, Jun. 19, 5:36 PM
Wed, Jun. 17, 10:08 AM
- BioCryst Pharmaceuticals (BCRX +1.8%) licenses Rapivab (peramivir injection), the world's only approved intravenous treatment for influenza, to Aussie biotech CSL Limited.
- CSL's subsidiary, bioCSL, will market the product globally with the exception of Japan, Korea, Taiwan and Israel. BioCryst also retains the right to pursue pandemic stockpiling orders for Rapivab from the U.S. government.
- Under the terms of the agreement, BioCryst will receive an upfront payment of $33.7M from bioCSL, up to $12M in milestones and tiered royalties on commercial sales. It will also be eligible to receive a percentage of the proceeds from government stockpiling purchases outside of the U.S.
- The FDA approved Rapivab, an intravenous viral neuraminidase inhibitor, in December 2014 for the treatment of acute uncomplicated influenza in adult patients who have been symptomatic for no more than two days.
Sun, May 10, 7:06 AM
- The World Health Organization has declared Liberia free of Ebola, marking the end of a national outbreak that infected as many as 400 new victims a week at its peak.
- Liberia has now gone 42 days - twice Ebola's maximum incubation period - since the burial of its last confirmed patient without discovering a new case.
- The disease is still spreading in Sierra Leone and Guinea, though at a slower pace. According to WHO statistics, more than 11,000 people have died from the virus, with about half of them in Liberia.
- Ebola-related stocks: JNJ, GSK, HEB, BCRX, NLNK, NNVC, INO, TKMR, OTCQB:GOVX, SRPT, CMRX, PLX, NSPH, LAKE, APT, VSR, SMED.
Fri, May 8, 9:19 AM
- BioCryst Pharmaceuticals (BCRX -0.2%) Q1 results: Revenues: $6.8M (+94.3%); R&D Expense: $17.1M (+85.9%); SG&A: $4.1M (+156.3%); Operating Loss: ($14.4M) (-94.6%); Net Loss: ($15.2M) (-50.5%); Loss Per Share: ($0.21) (-23.5%); Quick Assets: $108.6M (-4.7%).
- 2015 Guidance: Cash burn: $65M - 80M; Operating expenses: $75M - 95M.
Fri, May 8, 7:00 AM
Thu, May 7, 5:30 PM
Fri, May 1, 5:36 PM
Tue, Apr. 21, 9:42 AM
- Bristol-Myers Squibb (BMY +1.3%) upgraded to Overweight with $80 (21% upside) by Morgan Stanley.
- Align Technology (ALGN +4.6%) upgraded to Overweight with a $79 (46% upside) price target by Morgan Stanley.
- Biocryst Pharmaceuticals (BCRX +4.5%) upgraded to Neutral with $12 (20% upside) by Bank of America.
- Rosetta Genomics (ROSG -1%) upgraded to Buy with $5.50 (32% upside) price target by Cantor Fitzgerald.
- Phibro Animal Health (PAHC -2.7%) downgraded to Underweight with $35 (3% upside) price target by Morgan Stanley.
- Impax Laboratories (IPXL +0.5%) downgraded to Sell with $36 (28% downside risk) price target by UBS.
Wed, Apr. 1, 9:13 AM
Tue, Mar. 31, 5:36 PM
Tue, Mar. 31, 9:13 AM
Tue, Mar. 31, 8:31 AM
- The U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response's Biomedical Advanced Research and Development Authority (BARDA) awards BioCryst Pharmaceuticals (NASDAQ:BCRX) a contract for the continued development of BCX4430 for the potential treatment of diseases caused by RNA pathogens, including filoviruses.
- The base contract of $12.1M will support the manufacturing of BCX4430, while $22.9M in additional development options may be exercised by the government. The scope of the work in the base contract pertains to manufacturing, process improvement and scale-up over an 18-month period. The BCX4430 produced under the contract will be used in clinical trials and non-clinical toxicology studies that will support a New Drug Application (NDA) filing with the FDA for both intravenous and intramuscular formulations of BCX4430.
- President & CEO Jon P. Stonehouse says, "BCX4430 currently represents the only single drug that has demonstrated a survival benefit in non-human primates infected with Marburg or Ebola viruses. This new BARDA contract provides continuity in the ongoing development of our broad spectrum antiviral, '4430, and moves this program closer to the finish line."
- BCX4430 is an RNA dependent-RNA polymerase inhibitor that has shown broad-spectrum activity against in vitro against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses.
BCRX vs. ETF Alternatives
Other News & PR